IDEX Biometrics ASA IDXAF
—
0.89
0.00
0.00%
as of 24 Sep
- Market cap
- —
- P/E
- 0.0×
Follow IDXAF
Growth Flags
show if company had growth for consecutive years
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
231.15 | 269.93 | 119.06 | 19.34 | 8.84 | 0.10 | 22.22 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(17.03) | (46.65) | (44.07) | (11.85) | (9.92) | (0.02) | (4.01) |
P/B ratio |
5.50 | 23.62 | 8.96 | 3.46 | 3.23 | 0.02 | 6.50 |
Price to Tangible BV |
6.87 | 32.47 | 9.72 | 3.88 | 3.91 | 0.02 | 15.02 |
EV/Sales |
199.27 | 263.57 | 107.18 | 15.68 | 7.62 | 5.02 | 40.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(3.11) | (12.39) | (11.06) | (2.05) | (1.17) | (0.24) | (1.09) |
EV/FCF |
(3.11) | (12.31) | (11.00) | (2.03) | (1.16) | (0.24) | (1.11) |
Quick Ratio |
2.98 | 2.15 | 8.22 | 3.66 | 1.07 | 0.85 | 0.24 |
Current Ratio |
3.27 | 2.60 | 8.71 | 4.74 | 1.64 | 2.67 | 1.58 |
Net Debt/EBITDA |
0.44 | 0.28 | 1.14 | 0.50 | 0.20 | 0.00 | 0.00 |
Debt/Assets |
2.60% | 1.92% | 0.03% | 3.94% | 25.29% | 19.26% | 10.00% |
Debt/Equity |
0.03 | 0.03 | 0.00 | 0.05 | 0.56 | 0.42 | 0.52 |
Asset Turnover |
0.00 | 0.05 | 0.10 | 0.12 | 0.15 | 0.05 | 0.03 |
Operating CF/Net income |
0.84 | 0.87 | 0.85 | 0.96 | 1.01 | 1.21 | 0.86 |
Capex/Depreciation |
(0.52) | (0.19) | (0.08) | (0.20) | (0.15) | 0.05 | (0.09) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | (176.44%) | (129.59%) | (107.86%) | (155.84%) | (180.08%) | (323.95%) | |
| 0.00% | (132.20%) | (110.29%) | (91.95%) | (98.67%) | (81.96%) | (111.54%) | |
ROIC |
(466.23%) | (297.70%) | (492.68%) | (249.48%) | (266.50%) | (292.20%) | (436.26%) |
Return on Tangible Assets |
(242.32%) | (320.79%) | (94.74%) | (164.06%) | (304.89%) | (244.24%) | (378.58%) |
Average Days of Receivables |
691.26 | 550.00 | 193.30 | 203.24 | 170.06 | 404.06 | 527.38 |
Research and Development Expense of Revenue |
1,034.20% | 173.06% | 94.37% | 79.44% | 57.83% | 292.15% | 536.22% |
Selling, General and Administrative Expense of Revenue |
5,129.72% | 1,613.88% | 743.20% | 469.64% | 345.70% | 1,046.02% | 1,043.31% |
Intangible Assets out of Total Assets |
0.15 | 0.20 | 0.07 | 0.08 | 0.08 | 0.06 | 0.06 |
Share Based Compensation of Revenue |
596.93% | 251.60% | 96.83% | 66.51% | 31.01% | 41.74% | (185.04%) |
Graham Net Nets |
0.11 | 0.02 | 0.10 | 0.22 | 0.18 | 44.27 | 0.02 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(31.50%) | (10.38%) | (13.59%) | (38.93%) | (73.48%) | (17,829.00%) | (67.05%) |
Free Cash Flow Yield |
(27.72%) | (7.93%) | (8.18%) | (39.98%) | (74.52%) | (21,005.16%) | (162.62%) |
Revenue per Share |
0.35 | 0.71 | 1.55 | 1.99 | 1.64 | 0.20 | 0.01 |
Operating CF per Share |
(22.70) | (15.18) | (14.98) | (15.27) | (10.67) | (4.23) | (0.22) |
Capex per Share |
(0.71) | (0.22) | (0.08) | (0.13) | (0.10) | 0.03 | 0.00 |
Free Cash Flow per Share |
(23.41) | (15.40) | (15.06) | (15.40) | (10.77) | (4.20) | (0.22) |
Cash per Share |
11.80 | 4.76 | 18.37 | 7.85 | 4.49 | 0.49 | 0.02 |
Shareholders Equity per Share |
14.88 | 8.16 | 20.53 | 11.12 | 4.48 | 1.14 | 0.04 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
14.88 | 8.16 | 20.53 | 11.12 | 4.48 | 1.14 | 0.04 |
Free Cash Flow |
(28.02) | (23.63) | (27.67) | (31.64) | (27.25) | (17.42) | (8.64) |
Working Capital |
11.37 | 6.67 | 33.06 | 18.80 | 7.92 | 5.79 | 2.60 |
Capital Expenditures |
(0.85) | (0.33) | (0.14) | (0.27) | (0.24) | 0.11 | (0.04) |
Net Current Asset Value |
10.73 | 6.35 | 33.05 | 17.66 | 6.68 | 3.67 | 0.88 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
2.00 | 0.30 | 0.05 | 0.07 | 0.06 | (0.14) | 0.17 |
Net Profit Margin |
(7,646.93%) | (2,443.29%) | (1,146.20%) | (798.39%) | (643.52%) | (1,718.07%) | (3,937.80%) |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
0.81 | 1.03 | 1.39 | 1.22 | 2.01 | 20.63 | 11.40 |
Cash ROIC |
(89.66%) | (123.94%) | (40.33%) | (80.98%) | (95.92%) | (202.78%) | (294.05%) |
Accounts Receivable Turnover |
0.00 | 0.89 | 1.80 | 2.16 | 1.97 | 0.59 | 0.39 |
Accounts Payable Turnover |
0.00 | 0.50 | 1.91 | 2.92 | 3.51 | 2.19 | 0.61 |
Inventory Turnover |
0.00 | 0.36 | 1.20 | 1.14 | 0.72 | 0.28 | 0.11 |
Average Days of Payables |
2,725.73 | 837.51 | 199.38 | 173.27 | 64.26 | 184.23 | 690.64 |
Days of Inventory on Hand |
4,038.55 | 1,140.13 | 359.18 | 500.36 | 596.25 | 1,202.51 | 3,388.77 |
Average Receivables |
— | 1.23 | 1.58 | 1.89 | 2.10 | 1.43 | 0.65 |
Average Payables |
— | 0.55 | 0.66 | 1.11 | 1.11 | 0.77 | 1.00 |
Average Inventory |
— | 0.77 | 1.05 | 2.84 | 5.42 | 5.97 | 5.62 |
Average Assets |
— | 20.24 | 29.52 | 35.52 | 26.99 | 17.63 | 8.97 |
Average Common Equity |
— | 15.16 | 25.12 | 30.28 | 17.09 | 8.02 | 3.09 |
Columns are period end dates